Stockscreener 앱 받기
1.20
0.00%
0.00
시장 영업 전:
1.23
0.03
+2.50%
전일 마감가:
$1.20
열려 있는:
$1.24
하루 거래량:
861.17K
Relative Volume:
0.27
시가총액:
$41.95M
수익:
$3.25M
순이익/손실:
$-116.80M
주가수익비율:
-0.3934
EPS:
-3.05
순현금흐름:
$-98.17M
1주 성능:
+9.09%
1개월 성능:
+45.38%
6개월 성능:
-63.53%
1년 성능:
-94.97%
1일 변동 폭
$1.18
$1.27
1주일 범위
$1.13
$1.285
52주 변동 폭
$0.7893
$27.35
Rapt Therapeutics Inc Stock (RAPT) Company Profile
명칭
Rapt Therapeutics Inc
전화
(650) 489-9000
주소
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
RAPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
1.20 | 41.95M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-11-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-05-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | 개시 | Evercore ISI | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-09-14 | 개시 | Berenberg | Buy |
| 2023-08-09 | 개시 | Stifel | Buy |
| 2023-06-15 | 개시 | Barclays | Overweight |
| 2023-01-04 | 개시 | Guggenheim | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | CapitalOne | Overweight |
| 2022-05-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-09 | 개시 | JP Morgan | Overweight |
| 2021-08-12 | 개시 | SVB Leerink | Outperform |
| 2021-06-21 | 개시 | Piper Sandler | Overweight |
| 2020-06-01 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-13 | 개시 | ROTH Capital | Buy |
| 2019-11-25 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-25 | 개시 | UBS | Buy |
| 2019-11-25 | 개시 | Wells Fargo | Outperform |
모두보기
Rapt Therapeutics Inc 주식(RAPT)의 최신 뉴스
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC - Defense World
RAPT Therapeutics Plans Phase 2b Trials for RPT904 - TipRanks
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by Barclays PLC - Defense World
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
RAPT Therapeutics appoints new board chair By Investing.com - Investing.com Nigeria
RAPT Therapeutics appoints new board chair - Investing.com
RAPT Therapeutics, Inc. Announces Board Changes - Marketscreener.com
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors - Yahoo Finance
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.56 Average Target Price from Brokerages - MarketBeat
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of “Hold” from Analysts - Defense World
Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Grows By 25.5% - MarketBeat
Notable analyst calls this week: FREYR Battery, Apple and ServiceNow among top picks - Seeking Alpha
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright - Yahoo Finance
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to Buy Rating - Defense World
RAPT rockets 180% on licensing deal, $150M private placement (update) - MSN
RAPT Therapeutics Shares Surge After HC Wainwright Upgrade - Marketscreener.com
HC Wainwright & Co. Upgrades RAPT Therapeutics (RAPT) - MSN
RAPT upgraded at H.C. Wainwright on China licensing deal - MSN
RAPT stock upgraded at H.C. Wainwright (RAPT:NASDAQ) - Seeking Alpha
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to "Buy" Rating - MarketBeat
RAPT Therapeutics Announces License Agreement and Private Placement - Defense World
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement - Yahoo Finance
RAPT Therapeutics soars as it looks to raise $150M in private placement - MSN
RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement - Mugglehead
RAPT Therapeutics, Inc. announced that it expects to receive $149.976555 million in funding from a group of investors - Marketscreener.com
RAPT Therapeutics stock rises following licensing deal with Jemincare By Investing.com - Investing.com Nigeria
RAPT Therapeutics stock rises following licensing deal with Jemincare - Investing.com
Peninsula drugmaker lands $150 million, food allergy drug to fill pipeline holeSan Francisco Business Times - The Business Journals
Why RAPT Therapeutics Stock Gained Over 100% On Monday? - Yahoo Finance
US Stocks Mixed, Dow Tumbles 150 Points - Benzinga
Stock market today: iLearningEngines plunges by 60.44% while Reliance Global Group surged by 231.67% in early trading session - Business Upturn
RAPT Therapeutics secures rights to new allergy antibody - Investing.com
RAPT Therapeutics Partners with Jemincare and Secures Funding - TipRanks
RAPT Therapeutics prices 100M shares at 85c in private placement - TipRanks
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical - GlobeNewswire
RAPT Therapeutics Announces $150 Million Private Placement - GlobeNewswire
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement - The Bakersfield Californian
RAPT Therapeutics Secures $672.5M Deal for Breakthrough Anti-IgE Antibody with Extended Half-Life - StockTitan
Charles Schwab Investment Management Inc. Cuts Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? - MSN
RAPT Therapeutics stock plunges to 52-week low of $0.92 - Investing.com India
RAPT Therapeutics' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com
RAPT Therapeutics stock plunges to 52-week low of $0.92 By Investing.com - Investing.com Nigeria
RAPT Therapeutics stock plunges to 52-week low of $1 By Investing.com - Investing.com South Africa
RAPT Therapeutics stock plunges to 52-week low of $1 - Investing.com
HC Wainwright Has Optimistic Outlook of RAPT FY2024 Earnings - Defense World
HC Wainwright Reaffirms “Neutral” Rating for RAPT Therapeutics (NASDAQ:RAPT) - Defense World
RAPT scraps zelnecirnon program, stock plunges 46% (update) - MSN
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN
RAPT Therapeutics stock plunges to 52-week low of $1.11 By Investing.com - Investing.com UK
Rapt Therapeutics Inc (RAPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):